These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29979714)

  • 21. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
    Moorthy NS; Ramos MJ; Fernandes PA
    SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Propofol inhibits hERG K
    Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
    Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Catch-22 of Predicting hERG Blockade Using Publicly Accessible Bioactivity Data.
    Siramshetty VB; Chen Q; Devarakonda P; Preissner R
    J Chem Inf Model; 2018 Jun; 58(6):1224-1233. PubMed ID: 29772901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation.
    Diller DJ; Hobbs DW
    J Comput Aided Mol Des; 2007 Jul; 21(7):379-93. PubMed ID: 17549583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural analysis of hERG channel blockers and the implications for drug design.
    AlRawashdeh S; Chandrasekaran S; Barakat KH
    J Mol Graph Model; 2023 May; 120():108405. PubMed ID: 36680816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HergSPred: Accurate Classification of hERG Blockers/Nonblockers with Machine-Learning Models.
    Zhang X; Mao J; Wei M; Qi Y; Zhang JZH
    J Chem Inf Model; 2022 Apr; 62(8):1830-1839. PubMed ID: 35404051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.
    Tan Y; Chen Y; You Q; Sun H; Li M
    J Mol Model; 2012 Mar; 18(3):1023-36. PubMed ID: 21660488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
    Thai KM; Ecker GF
    Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
    Leong MK
    Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational investigations of hERG channel blockers: New insights and current predictive models.
    Villoutreix BO; Taboureau O
    Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. General Purpose 2D and 3D Similarity Approach to Identify hERG Blockers.
    Schyman P; Liu R; Wallqvist A
    J Chem Inf Model; 2016 Jan; 56(1):213-22. PubMed ID: 26718126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating cardiotoxicity related with hERG channel blockers using molecular fingerprints and graph attention mechanism.
    Wang T; Sun J; Zhao Q
    Comput Biol Med; 2023 Feb; 153():106464. PubMed ID: 36584603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revealing the structural basis of action of hERG potassium channel activators and blockers.
    Perry M; Sanguinetti M; Mitcheson J
    J Physiol; 2010 Sep; 588(Pt 17):3157-67. PubMed ID: 20643767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular determinants of R-roscovitine block of hERG channels.
    Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
    PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of hERG potassium channel affinity by the CODESSA approach.
    Coi A; Massarelli I; Murgia L; Saraceno M; Calderone V; Bianucci AM
    Bioorg Med Chem; 2006 May; 14(9):3153-9. PubMed ID: 16426850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.